Epithalon: Telomerase Activation Claims and the Risk Question
A synthetic tetrapeptide analog of a natural pineal gland peptide, studied for telomerase activation and circadian regulation.
What is Epithalon?
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), designed as an analog of epithalamin, a naturally occurring pineal gland peptide. It has been studied — primarily by Russian researchers, notably Vladimir Khavinson's group — in small and preclinical studies for telomerase activation, pineal gland/melatonin regulation, and circadian rhythm effects. It's sold exclusively as a research compound; no FDA approval or large-scale human trial exists.
Quick facts
- Molecular Formula
- C14H22N4O9
- Molecular Weight
- 390.35 g/mol
- CAS Number
- 307297-39-8
- Sequence
- Ala-Glu-Asp-Gly (AEDG)
- Class
- Synthetic tetrapeptide, pineal peptide analog
- Brand Names
- No trademarked brand — sold as a research compound
- Legal Status
- Not FDA-approved for human use — research use only (RUO)
- Category
- Longevity & Healthspan
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
10mg vial + 2mL bacteriostatic water = 5000mcg/mL. Run the numbers in the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
Epithalon Mechanism of Action
Pineal Peptide Analog
Epithalon (AEDG: Ala-Glu-Asp-Gly) is a synthetic tetrapeptide designed to mimic epithalamin, a naturally occurring pineal gland peptide extract. Research interest centers on the pineal gland's role in regulating melatonin production and, by extension, circadian rhythm and sleep-wake cycling.
Telomerase Activation Research
Epithalon is best known for preclinical research (Khavinson et al.) investigating telomerase activation — the enzyme that maintains telomere length at chromosome ends — in cell culture and animal models. This research forms the basis of its popularity in longevity circles, though direct human evidence for telomerase effects remains limited.
Epithalon Dosage and Protocols
The Khavinson-Style Cycling Protocol
The most commonly cited research protocol uses 5–10mg daily via subcutaneous injection for a 10–20 day course, repeated a few times per year rather than used continuously. This cycling pattern comes from the original Khavinson-group research design, not from a formal human dose-finding trial.
Epithalon Side Effects and Safety
Limited Safety Data
No formal human safety or tolerability data exists for epithalon at scale. Given its studied interest in telomerase and cell-cycle-related pathways, active malignancy is treated as a precautionary contraindication until more is understood about its effects in that context. Pregnancy is also a precautionary contraindication.
Epithalon Research Evidence
Small Studies, Mostly Preclinical
The bulk of epithalon's published research comes from a small number of research groups, primarily in Russia, using small sample sizes and older publication standards. Cell-culture and animal studies suggest effects on telomerase activity and circadian markers, but rigorous, independently replicated human randomized controlled trials are lacking.
Regulatory and Legal Status
Epithalon has no FDA-approved indication and is not approved for human consumption. It is sold exclusively as a research-grade compound (RUO). No formal human pharmacokinetic or dose-finding study has been conducted. Researchers and users should verify the legal status of epithalon in their jurisdiction prior to purchase or use.
Epithalon Stacking and Combinations
Circadian/Sleep Research Stack
Epithalon is sometimes paired with DSIP in sleep- and circadian-focused research protocols, combining epithalon's pineal/melatonin-pathway research angle with DSIP's studied delta-sleep-inducing effects. No formal trial data exists for this or any epithalon combination.
Epithalon Pharmacokinetics
No Published Half-Life
No study has directly measured epithalon's plasma half-life in humans. Based on the general pharmacokinetics of short, unmodified peptides — which typically show plasma half-lives of 2–15 minutes — epithalon's circulating half-life is expected to be on the order of minutes, though this is an extrapolation rather than a confirmed measurement.
Contraindications
- pregnancy
- active malignancy
Frequently asked questions
What is a typical Epithalon dose?
Published research protocols report 5–10 mg, daily, 10–20 day cycles. This is the range described in the literature, not a recommendation.
What is the half-life of Epithalon?
Expected on the order of minutes (unmodified short peptide) — no direct human plasma half-life study has been published.
Is Epithalon backed by strong evidence?
Epithalon carries a REGEN research grade of D. REGEN Research Tier D — human reports are almost entirely from a single Russian research group, without independent replication.
How is Epithalon administered?
Routes reported in the literature: subcutaneous.
Who should avoid Epithalon?
Contraindications noted in the literature include pregnancy, active malignancy.